FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1544043065> ?p ?o ?g. }

• W1544043065 endingPage "1907" @default.
• W1544043065 startingPage "1898" @default.
• W1544043065 abstract "BACKGROUND The determination of in situ protein levels of ERCC1 with the 8F1 monoclonal antibody is prognostic of survival in patients with non‐small cell lung cancer (NSCLC). The authors previously demonstrated that 8F1 recognizes a second nuclear antigen. This antigen was identified and its value as a biomarker of clinical outcomes analyzed. METHODS The second antigen was identified by mass spectrometry. Protein identity and antibody specificity were confirmed through knockdown and overexpression experiments. Immunohistochemistry of 187 early‐stage NSCLC samples and 60 head and neck squamous cell carcinomas (HNSCCs) was used to examine the influence of the second antigen on 8F1 immunoreactivity and its association with patient outcomes. RESULTS Choline phosphate cytidylyltransferase‐α (CCTα, also known as phosphate cytidylyltransferase 1 choline alpha [PCYT1A], a phospholipid synthesis enzyme regulated by RAS) is the second antigen recognized by 8F1. In NSCLC samples, CCTα contributed (rho, 0.38) to 8F1 immunoreactivity. In samples of squamous cell carcinomas of the lung, CCTα was found to be the dominant determinant of 8F1 immunoreactivity, whereas its contribution in other subtypes of lung cancer was negligible. High expression of CCTα, but not ERCC1, was found to be prognostic of longer disease‐free survival (log‐rank P = .002) and overall survival (log‐rank P = .056). Similarly, in patients with HNSCC, CCTα contributed strongly to 8F1 immunoreactivity (rho, 0.74), and high CCTα expression was found to be prognostic of survival (log‐rank P = .022 for disease‐free survival and P = .027 for overall survival). CONCLUSIONS CCTα is the second antigen detected by 8F1. High CCTα expression appears to be prognostic of survival in patients with NSCLC who are treated by surgery alone and patients with HNSCC. CCTα is a promising biomarker of patient survival and deserves further study. Cancer 2014;120:1898–1907 . © 2014 American Cancer Society ." @default.
• W1544043065 created "2016-06-24" @default.
• W1544043065 creator A5001557696 @default.
• W1544043065 creator A5024869932 @default.
• W1544043065 creator A5027863398 @default.
• W1544043065 creator A5045078529 @default.
• W1544043065 creator A5054160947 @default.
• W1544043065 creator A5059603398 @default.
• W1544043065 creator A5060699409 @default.
• W1544043065 creator A5066523907 @default.
• W1544043065 creator A5080595928 @default.
• W1544043065 creator A5084187205 @default.
• W1544043065 creator A5088949525 @default.
• W1544043065 date "2014-04-01" @default.
• W1544043065 modified "2023-10-16" @default.
• W1544043065 title "Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas" @default.
• W1544043065 cites W1514632623 @default.
• W1544043065 cites W1555396697 @default.
• W1544043065 cites W1964636811 @default.
• W1544043065 cites W1975088494 @default.
• W1544043065 cites W1982602899 @default.
• W1544043065 cites W1985097678 @default.
• W1544043065 cites W2001773803 @default.
• W1544043065 cites W2004718750 @default.
• W1544043065 cites W2005599761 @default.
• W1544043065 cites W2010293177 @default.
• W1544043065 cites W2010624323 @default.
• W1544043065 cites W2010900338 @default.
• W1544043065 cites W2016988125 @default.
• W1544043065 cites W2051256772 @default.
• W1544043065 cites W2054460645 @default.
• W1544043065 cites W2076597529 @default.
• W1544043065 cites W2090439479 @default.
• W1544043065 cites W2098363392 @default.
• W1544043065 cites W2100776825 @default.
• W1544043065 cites W2105131166 @default.
• W1544043065 cites W2112503651 @default.
• W1544043065 cites W2116945755 @default.
• W1544043065 cites W2119165414 @default.
• W1544043065 cites W2120369670 @default.
• W1544043065 cites W2124537819 @default.
• W1544043065 cites W2128172210 @default.
• W1544043065 cites W2137090431 @default.
• W1544043065 cites W2140679291 @default.
• W1544043065 cites W2145629140 @default.
• W1544043065 cites W2156380335 @default.
• W1544043065 cites W2157216866 @default.
• W1544043065 cites W2165963900 @default.
• W1544043065 cites W2172030256 @default.
• W1544043065 doi "https://doi.org/10.1002/cncr.28643" @default.
• W1544043065 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4047200" @default.
• W1544043065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24692084" @default.
• W1544043065 hasPublicationYear "2014" @default.
• W1544043065 type Work @default.
• W1544043065 sameAs 1544043065 @default.
• W1544043065 citedByCount "22" @default.
• W1544043065 countsByYear W15440430652015 @default.
• W1544043065 countsByYear W15440430652016 @default.
• W1544043065 countsByYear W15440430652017 @default.
• W1544043065 countsByYear W15440430652018 @default.
• W1544043065 countsByYear W15440430652019 @default.
• W1544043065 countsByYear W15440430652020 @default.
• W1544043065 countsByYear W15440430652021 @default.
• W1544043065 countsByYear W15440430652022 @default.
• W1544043065 countsByYear W15440430652023 @default.
• W1544043065 crossrefType "journal-article" @default.
• W1544043065 hasAuthorship W1544043065A5001557696 @default.
• W1544043065 hasAuthorship W1544043065A5024869932 @default.
• W1544043065 hasAuthorship W1544043065A5027863398 @default.
• W1544043065 hasAuthorship W1544043065A5045078529 @default.
• W1544043065 hasAuthorship W1544043065A5054160947 @default.
• W1544043065 hasAuthorship W1544043065A5059603398 @default.
• W1544043065 hasAuthorship W1544043065A5060699409 @default.
• W1544043065 hasAuthorship W1544043065A5066523907 @default.
• W1544043065 hasAuthorship W1544043065A5080595928 @default.
• W1544043065 hasAuthorship W1544043065A5084187205 @default.
• W1544043065 hasAuthorship W1544043065A5088949525 @default.
• W1544043065 hasBestOaLocation W15440430652 @default.
• W1544043065 hasConcept C104317684 @default.
• W1544043065 hasConcept C104451858 @default.
• W1544043065 hasConcept C121608353 @default.
• W1544043065 hasConcept C126322002 @default.
• W1544043065 hasConcept C134935766 @default.
• W1544043065 hasConcept C142724271 @default.
• W1544043065 hasConcept C147483822 @default.
• W1544043065 hasConcept C159654299 @default.
• W1544043065 hasConcept C203014093 @default.
• W1544043065 hasConcept C204232928 @default.
• W1544043065 hasConcept C2776256026 @default.
• W1544043065 hasConcept C2776530083 @default.
• W1544043065 hasConcept C2776833033 @default.
• W1544043065 hasConcept C2779309665 @default.
• W1544043065 hasConcept C2781197716 @default.
• W1544043065 hasConcept C502942594 @default.
• W1544043065 hasConcept C542903549 @default.
• W1544043065 hasConcept C55493867 @default.
• W1544043065 hasConcept C71924100 @default.
• W1544043065 hasConcept C86803240 @default.

• next